Gastroesophageal Junction Adenocarcinoma Clinical Trials in Chūōku
2 recruitingChūōku, Japan
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled284 locationsNCT06764875
Recruiting
Phase 2
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Toray Industries, Inc146 enrolled27 locationsNCT06038578